Abstract: The present disclosure relates to a method for detecting methylation of the bowel-cancer-specific methylation marker GPM6A (NM_201591, glycoprotein M6A) gene in order to diagnose bowel cancer, and more specifically relates to a method for providing information for diagnosing bowel cancer by detecting the methylation of a bowel-cancer-specific marker gene that is specifically methylated in bowel cancer cells. The method for detecting methylation and a diagnostic composition, kit and nucleic-acid chip according to the present disclosure can be used to advantage in diagnosing bowel cancer more accurately and quickly than by normal methods as they permit bowel cancer to be diagnosed at the initial genetic transformation step and so allow early diagnosis.

Abstract: Methods and kits for identifying a subject having pre-cancerous advanced polyps or colorectal cancer based on the expression profile(s) of specific mRNA biomarkers. Methods and kits for diagnosing, preventing, managing therapy, monitoring and identifying predisposition to colorectal cancer.

Abstract: The present disclosure relates to methods of treating autoimmune conditions in patients who have genetic alterations in the TNFRSF6B gene, which codes for the decoy receptor 3 protein (DcR3), for example that reduce the expression, secretion, or ligand binding activity of DcR3. For example, in some embodiments, the conditions may be treated with molecules that inhibit the activity of DcR3 ligands such as LIGHT, TL1A, and FasL, such as anti-LIGHT, anti-TL1A, and anti-FasL antibodies, or inhibitors of the non-canonical NF-?B pathway.

Abstract: The present invention provides methods and compositions involving genetic markers and their association with oral mucositis occurring in patients who are treated with cancer therapy and/or conditioning therapy for hematopoietic stem cell transplantation.

Abstract: The present invention provides methods for predicting the pattern of locomotion in a horse including the ability of a horse to use different gaits and the ability to trot at a fast speed. The methods comprise determining in a sample of DNA obtained from a horse the presence or absence of at least one genetic marker, wherein said at least one genetic marker is located on horse chromosome 23, said marker being associated with the ability to use different gaits. The invention further provides primers that amplify markers being associated with the ability to use different gaits and hybridization probes to detect markers being associated with the ability to use different gaits and the ability to trot at a fast speed.

Abstract: The invention provides to RAF1 gene fusions, RAF1 fusion proteins, and fragments of those genes and polypeptides. The invention further provides methods of diagnosing and treating diseases or disorders associated with RAF1 fusions, such as conditions mediated by aberrant RAF1 expression or activity, or overexpression of RAF1.

Abstract: FGR (feline Gardner-Rasheed sarcoma viral oncogene homolog) fusions are described herein. Further provided are methods of diagnosing and treating diseases or disorders associated with FGR fusions, such as conditions mediated by FGR aberrant activity, or overexpression.

Abstract: The invention provides TERT gene fusions, TERT fusion proteins, and fragments of those genes and polypeptides. The invention further provides methods of diagnosing diseases or disorders associated with TERT fusions, such as conditions mediated by aberrant TERT expression or activity, or overexpression of TERT.

Abstract: The invention provides PRKC gene fusions, PRKC fusion proteins, and fragments of those genes and polypeptides. The invention further provides methods of diagnosing and treating diseases or disorders associated with PRKC fusions, such as conditions mediated by aberrant PRKC expression or activity, or overexpression of PRKC.

Abstract: Provided herein is technology for colorectal neoplasia screening and particularly, but not exclusively, to methods, compositions, and related uses for detecting the presence of colorectal neoplasia in 1) individuals at, older or younger than 50 years of age, or 2) individuals having Lynch Syndrome.

Abstract: Methods and kits are provided for screening a patient for bladder cancer. Embodiments include those involving centromeric probes to chromosomes 3, 7, and 10 and a locus-specific probe to 5p15.

Abstract: The subject invention pertains to biomarkers for identifying the source of a cell as a current, former, or never smoker. In certain embodiments, the methylation status at the AHRR locus in the genomic DNA isolated from a cell is determined by pyrosequencing technique using specific primers described herein. Kits containing primers and reagents for carrying out the methods disclosed herein are also provided.

Abstract: The present invention provides methods for identifying metastases by detecting nucleic acid hypermethylation of one or more genes in one or more samples, and in particular in the lymph nodes. The invention further relates to DNA methylation as a predictor of disease recurrence and patient prognosis, specifically in the field of cancer biology.

Abstract: A method for analyzing cell free DNA (cfDNA) from the bloodstream of a cancer patient is provided. In some embodiments, the method may comprise sequencing at least part of the coding sequences of TP53 and KRAS in a sample of the cfDNA, analyzing the sequences to identify nucleotide transversions in the coding sequences of the genes, relative to reference sequences of the genes. In some embodiments, the method may comprise counting the total number of identified nucleotide transversions. The presence of nucleotide transversions indicates that the patient will be more responsive to the immune checkpoint inhibitor, whereas a decreased number of transversions or no transversions indicates that the patient will be less responsive to the immune checkpoint inhibitor.

Abstract: Specific mutations of FGFR3 (S249C) and of TP53 (V272M) are identified as being characteristic of breast cancer, and of having utility in diagnosis and prognosis of an individual with breast cancer. Systems and methods useful for identification of such mutations are also presented.

Abstract: Disclosed herein are methods of detecting presence of a gene fusion in a sample from a subject. In some embodiments, the methods of detecting presence of a fusion gene in a sample from a subject utilize a fusion probe that spans the point of fusion between two nucleic acids or genes, and detecting the fusion probe after nuclease treatment. In other embodiments, the methods of detecting presence of a fusion gene in a sample from a subject utilize two or more probes that flank the point of fusion between two nucleic acids or genes, and detecting these probes after nuclease treatment. In additional embodiments, the methods can include determining the percentage of gene fusion in the sample relative to the first nucleic acid or the second nucleic acid.

Abstract: The present invention relates to a DNA sequence showing difference between the female and male individuals of Litopenaeus vannamei and its corresponding acquired method. The method comprises: respectively conducting high-through put sequencing on the mixing pools of female individuals and male individuals in by high-through put sequencing platform; conducting bioinformatic analysis on the sequencing results to screen out sequences showing significant difference between the mixing pools of female and male individuals; verifying the obtained sex difference sequence in individuals from different sources; and finally, obtaining a probe sequence for female and male identification of L. vannamei, so that the genetic sex of this species can be accurately identified using the sequences. The method of the present invention has the characteristics of high efficiency, accuracy and reliability, and possess broad application potential in the early sex identification and sex control research of prawns.

Abstract: The present invention relates to the field of biomarkers. More specifically, the present invention relates to the use of biomarkers to predict suicide ideation and/or suicide attempt. In one embodiment, a method for predicting suicide ideation and/or attempt by a subject comprises the steps of (a) measuring the DNA methylation level of a CpG dinucleotide in the 3? untranslated region of SKA2; (b) identifying the genotype at a SNP within the 3? UTR of SKA2, and (c) predicting suicide ideation and/or attempt by the subject using a prediction algorithm.

Abstract: The present invention relates to the novel use of syndecan-2 (SDC2) gene as a CpG methylation biomarker for detecting precancerous lesions, and more particularly, to the use of the SDC2 gene as a biomarker to early diagnose colorectal precancerous lesions by measuring the degree of methylation of the SDC2 gene. The present invention provides a method of providing information for diagnosis of precancerous lesions by detecting methylation of the CpG islands of the SDC2 gene. In addition, the use of the methylation detection and kit according to the present invention makes it possible to diagnose colorectal precancerous lesions at an early transformation stage, thus enabling the early diagnosis of colorectal precancerous lesions. Furthermore, the methylation detection method and kit of the present invention enables colorectal precancerous lesions to be effectively diagnosed in an accurate and rapid manner compared to conventional methods.

Abstract: This invention relates to a method of diagnosing the depression, and more particularly to a method and kit for diagnosing depression after acute coronary syndrome, by measuring the concentration of a specific biomarker in the blood of a patient suffering from acute coronary syndrome to predict depression after acute coronary syndrome.